Watson Gets FDA Approval for Generic Pain Drug
Posted on: Wednesday, 28 November 2007, 15:00 CST
Watson Pharmaceuticals has received final approval from the FDA on its abbreviated new drug application for its drug combination of oxycodone hydrochloride and ibuprofen tablets in the 5mg/400mg strength.
Watson's oxycodone hydrochloride and ibuprofen product is the generic equivalent to Forest Laboratories's Combunox, which is indicated for the short-term (not more than seven days) management of acute, moderate to severe pain.
Watson intends to launch its oxycodone hydrochloride and ibuprofen product immediately.
Source: Datamonitor
Related Articles
- Covidien Announces Agreement With Purdue Pharma L.P. Enabling Launch of Oxycodone Hydrochloride Extended-Release Tablets
- FDA Accepts Watson's NDA for Bladder Drug
- Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
- Watson Receives FDA Final Approval for Generic Wellbutrin
- Authorities Approve Watson's Andrx Acquisition
- Elite Pharmaceuticals Successfully Concludes Second Pilot Phase I Trial of Its Once-Daily Oxycodone Hydrochloride Product; Positive Results From Second Oxycodone HCL Product in Clinical Trials
- IMPAX Signs Exclusive Supply and Distribution Agreement With DAVA Pharmaceuticals for Oxycodone Hydrochloride Extended Release Tablets
- New Research Suggests Oxycodone May Be More Effective Than Morphine in Treatment of Visceral Pain
- New COMBUNOX(TM) (Oxycodone HCl and Ibuprofen) Tablets (CII) Now Available for the Short-Term Treatment of Acute, Moderate to Severe Pain
Rating: 3.0 / 5 (7 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds